

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

TNNT1 RABBIT PAB

Cat.#: S219300

Product Name: Anti-TNNT1 Rabbit Polyclonal Antibody

Synonyms: ANM; TNT; NEM5; STNT; TNTS

UNIPROT ID: P13805 (Gene Accession - BC010963)

Background: This gene encodes a protein that is a subunit of troponin, which is a regulatory complex located on the thin filament of the sarcomere. This complex regulates striated muscle contraction in response to fluctuations in intracellular calcium concentration. This complex is composed of three subunits: troponin C, which binds calcium, troponin T, which binds tropomyosin, and troponin I, which is an inhibitory subunit. This protein is the slow skeletal troponin T subunit. Mutations in this gene cause nemaline myopathy type 5, also known as Amish nemaline myopathy, a neuromuscular disorder characterized by muscle weakness and rod-shaped, or nemaline, inclusions in skeletal muscle fibers which affects infants, resulting in death due to respiratory insufficiency, usually in the second year. Multiple transcript variants encoding different isoforms have been found for this gene.

Immunogen: Fusion protein of human TNNT1

Applications: ELISA, IHC

Recommended Dilutions: IHC: 50-200; ELISA: 5000-10000

Host Species: Rabbit

Clonality: Rabbit Polyclonal

Isotype: Immunogen-specific rabbit IgG


Purification: Antigen affinity purification

Species Reactivity: Human

Constituents: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

Research Areas: Signal Transduction

Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing



Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 219300(TNNT1 Antibody) at a dilution of 1/75(Cytoplasm).

In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the fusion protein and then with 219300(Anti-TNNT1 Antibody) at dilution 1/75.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010